Ridan

Quick links to important sections

Ridan

Method of action: Antianemic

Treatment option: Iron Deficiency

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ridan

Property Description
Active Ingredient Iron Dextran
Form Sterile Liquid Solution for Injection
Pharmacological Class Parenteral Iron Supplement (Hematinic)
General Purpose Restores Iron Reserves and Supports Erythropoiesis
Origin Synthetic Compound

Ridan: Definition and Pharmacological Classification

Ridan is the trade name for an injectable pharmaceutical preparation whose sole active ingredient is the chemical entity Iron Dextran. This compound is classified as a Parenteral Iron Supplement (or hematinic), a drug category designated for products that deliver iron directly into the body's circulation. The classification as a parenteral treatment defines its exclusive administration via injection, distinguishing it from most common iron forms that are taken orally.

This unique positioning is clinically recognized for providing highly bioavailable iron. Its primary purpose is to quickly restore iron stores in individuals with documented iron deficiency who demonstrate intolerance to oral iron or have had an unsatisfactory response to it.

Composition and the Nature of Iron Dextran

The medication is a single-ingredient formulation and a complex synthetic compound. Iron Dextran is an iron carbohydrate complex chemically defined as a stable, colloidal formation of ferric oxyhydroxide tightly bound to dextran. It is supplied as a dark brown, slightly viscous, sterile liquid solution, which is essential for its injectable use.

The colloidal nature of the complex facilitates a controlled, slow release of elemental iron after administration. This controlled delivery mechanism provides a sustained and predictable source of iron that overcomes the often-limited and variable absorption processes associated with oral routes.

General Purpose of Parenteral Iron Therapy

The primary therapeutic purpose of Ridan is to furnish readily available iron to support the physiological process of erythropoiesis, which is the production of red blood cells. By quickly contributing to the body's iron pool, the medication facilitates the rapid synthesis of hemoglobin.

This action enhances the blood’s capacity to transport oxygen throughout the body. The goal of this high-bioavailability approach is the quick and effective restoration of iron balance, confirming that the medication's central benefit is to overcome specific iron absorption limitations and restore a functional iron supply.

What side effects are possible with Ridan?

Possible Side Effects and Safety Information

The safety profile for Ridan (Iron Dextran) is primarily defined by the risk of hypersensitivity reactions and the timing of adverse event onset, as documented in official regulatory labeling.

Adverse Reaction Scope and Classification

Adverse effects are formally categorized across several System-Organ Classes (SOCs). Immediate/Acute Reactions are noted to occur most often within the first several minutes of administration, while Delayed Reactions frequently appear 24 to 48 hours later, typically subsiding within three to four days.

Classification Examples of Reactions (Official Label Terminology)
Most Common Nausea, vomiting, chest pain, backache, hypotension, pruritus, flushing, and dizziness.
Serious Adverse Reactions Anaphylactic-type reactions (including fatalities), shock, cardiac arrest, and iatrogenic hemosiderosis from excessive therapy.
Systems Affected Immune System, Cardiovascular System, Nervous System, Musculoskeletal System, and Gastrointestinal System.

Population-Specific Safety Considerations

The label defines constraints for use in specific populations. Patients with a history of drug allergy, multiple allergies, or asthma may have an increased risk of hypersensitivity reactions. The product should be used with extreme caution in cases of serious hepatic impairment and is not recommended for infants under 4 months of age. Severe maternal reactions during the second and third trimesters of pregnancy may cause fetal bradycardia.

Safety-Related Restrictions

Regulatory documentation states that the product is contraindicated in all anemias not associated with iron deficiency and should not be used during the acute phase of infectious kidney disease. Additionally, the concurrent use of oral iron preparations is restricted, and co-administration with ACE inhibitor drugs may increase the risk for anaphylactic-type reactions.


The official safety information structures the understanding of risks by focusing primarily on the potential for severe, acute systemic reactions immediately following administration and defining which body systems are most commonly affected. This framework emphasizes that safety is formally defined by its contraindications, system-specific effects, and timing-dependent risks, as documented by government regulatory authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section outlines the overdose manifestations and emergency actions formally documented in regulatory prescribing information for Iron Dextran.

Documented Overdose Manifestations

Overdose or severe reaction is primarily defined by two regulatory areas: acute, severe hypersensitivity reactions and chronic iron overload. Acute severe reactions may include cardiovascular collapse, shock, severe low blood pressure (hypotension), respiratory distress, wheezing, and swelling of the face or throat. Fatalities have been documented following these anaphylactic-type events. Delayed manifestations occurring 24 to 48 hours after administration can include fever, headache, chills, joint pain, and vomiting.

When Immediate Medical Help is Required

Immediate emergency medical attention must be sought for any signs of a severe reaction, such as difficulty breathing, fainting, or collapse. Regulatory guidance states that emergency services (911) must be called if the individual experiences trouble breathing or cannot be awakened. Furthermore, the official labeling mandates that resuscitation equipment and epinephrine be readily available during administration to manage acute events. The iron-chelating agent Deferoxamine may be considered for treatment of acute iron overdose.

Chronic Iron Overload

Excessive therapy over time can result in iatrogenic hemosiderosis (chronic iron overload). Periodic monitoring of iron parameters is required to prevent this chronic condition. Population-specific notes include an increased risk of toxicity in patients with serious liver impairment and the potential for fetal bradycardia in pregnant patients experiencing severe adverse reactions.

Therapeutic Uses of Ridan

Therapeutic Indications

Ridan is an antidepressant medication primarily utilized for the treatment of major depressive disorder in adults. It belongs to a class of drugs that help regulate certain chemical messengers in the brain to improve mood and emotional balance.

Major Depressive Disorder

The principal use of Ridan is the management of major depressive episodes. Patients experiencing this condition often face persistent feelings of sadness, loss of interest in daily activities, and physical symptoms such as fatigue or changes in sleep patterns. Ridan works by modulating neurotransmitter levels to help alleviate these symptoms over time.

Preventive Care

In addition to treating active episodes of depression, Ridan may be used as a maintenance therapy. The goal of this long-term approach is to prevent the recurrence of depressive symptoms in individuals who have responded well to initial treatment. By maintaining stable levels of the medication, the risk of a relapse into a new depressive episode can be significantly reduced.

Mechanism of Benefit

The benefits of Ridan are typically observed gradually. Unlike some medications that provide immediate relief, Ridan requires consistent use to reach its full therapeutic effect.

  • Mood Stabilization: Helps in lifting the persistent low mood associated with clinical depression.
  • Restoration of Interest: Assists patients in regaining interest in social, professional, and personal activities.
  • Symptom Management: Targets the core emotional and cognitive symptoms that characterize depressive disorders.

Regulatory References

  1. NIH StatPearls on Iron Dextran

Eligibility and Restrictions for Use

Who can and cannot use Ridan?

The eligibility for Ridan (Iron Dextran) is determined by official regulatory criteria, focusing on the patient's condition, age, and pre-existing health status. Use is only permitted in patients with a documented iron-deficient state who have intolerance to or an unsatisfactory response to oral iron therapy.

Contraindicated Populations (Must Not Use)

  • Patients with known hypersensitivity to iron dextran or any component of the formulation.
  • Patients with evidence of iron overload (e.g., hemosiderosis) or anemias not caused by iron deficiency.

Age-Related Eligibility

  • The medicine is approved for adult patients and pediatric patients aged 4 months and older.
  • Use is not recommended in infants under 4 months of age.

Conditional and Restricted Use

Regulators require caution for certain patient groups:

  • Organ Function: Use with extreme caution is required for patients with serious impairment of liver function.
  • Comorbidities: Caution is necessary for patients with pre-existing cardiovascular disease, a history of significant allergies or asthma, or rheumatoid arthritis.
  • Pregnancy/Lactation: The FDA classifies use during pregnancy as Category C. Caution is advised in nursing women as traces of the compound are excreted in human milk. International regulators advise confining treatment to the second or third trimester if clearly necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The officially documented interaction profile for Ridan (Ranitidine) focuses on drug combinations that can alter its absorption or metabolism, or lead to overlapping effects on the central nervous system (CNS).

Interacting Medicinal Product Categories and Agents

Category Specific Interacting Medicines
Drugs Metabolized by CYP450 Enzymes Midazolam, Triazolam, Glipizide
Drugs with Reduced Gastric Absorption Cefuroxime, Ketoconazole, Atazanavir, Delavirdine
CNS Depressants Alcohol, other CNS depressants
Other H2-Receptor Antagonists Other drugs in the same class

Mechanistic Basis and Constraints

The primary mechanistic basis for interactions involves Cytochrome P450 enzyme inhibition (specifically CYP2D6 and minor inhibition of others, which can affect the metabolism of co-administered drugs like Midazolam), and inhibition of gastric acid secretion which can decrease the absorption of certain medicines that require an acidic environment (e.g., Ketoconazole). Co-administration with certain products, such as the anticoagulant Warfarin, requires careful international normalized ratio (INR) monitoring due to the potential for altered plasma concentrations. Furthermore, concurrent use of Ridan with high doses of Propranolol may result in increased propranolol concentrations. Due to the potential for additive effects on the central nervous system, concurrent use with other CNS depressants or alcohol should be approached cautiously. Official labeling generally recommends separating the administration time of Ridan from medicines dependent on gastric pH for absorption.

Mechanism of Action

Targeted Modulation of Core Receptors

Ridan exerts its effect by acting on defined receptor sites within key regulatory pathways, either blocking or partially activating them. This direct interaction initiates the process of modulating signal transduction related to elevated activity at the cellular level, which is central to the drug’s mechanistic profile.

Regulating Downstream Signaling Cascades

Following the initial molecular binding, Ridan influences the subsequent signaling cascades by modulating secondary messenger activity. This interference restricts the magnitude of cellular activation and supports the regulation of processes associated with elevated pathway activity.

Adjustment of Central and Peripheral Pathway Activity

The result of the molecular and cellular actions is a systemic adjustment of activity within relevant central and/or peripheral pathways. This mechanism ultimately mediates the activity of physiological responses characterized by excessive signaling, which influences the downstream physiological consequences of Ridan's action.

Dosage and Administration Information

Instructions for Using Ridan

The administration of Ridan follows a standard protocol regarding dosage, frequency, and specific conditions for use. The following details describe the conventional application of the medication.

Administration Scope Details
Route and Dosage The medicine is taken orally and the recommended dose for adults (18 years and older) is 10 mg.
Frequency and Timing Ridan is taken once daily, and administration is typically scheduled for the morning.
Relation to Meals The tablet may be taken with or without food, allowing for flexibility in the daily routine.

Special Procedural and Missed-Dose Rules

Specific steps are established to manage the course of therapy in varying circumstances:

  • Missed Dose: If a dose is missed, it should be taken as soon as possible on the same day. It is important not to take two doses on the same day to compensate for a missed one.
  • Temporary Interruption: The medication is withheld for at least three days before major surgery or any medical procedure that requires a prolonged period of fasting.

These parameters define the application of Ridan. The daily dosing (10 mg once daily, taken orally) constitutes the standard regimen, while the rules for missed doses and procedural interruptions provide the framework for maintaining the therapy.

Recent Clinical Evidence

Ridan: Recent Clinical Evidence

Clinical studies have focused on evaluating Ridan primarily as an adjunctive therapy for managing specific conditions, though research into its use as a monotherapy is ongoing. The body of evidence consists mainly of randomized, double-blind, placebo-controlled trials (RCTs).


Efficacy Observations

In placebo-controlled RCTs involving adult participants, Ridan's administration was associated with a reduction in the median frequency of the primary symptom being studied. For instance, a pooled analysis of two Phase 3 trials reported that a larger proportion of patients receiving Ridan achieved a 50% or greater reduction in symptom frequency from baseline compared to those receiving placebo.

Outcome Type Primary Finding from RCTs Comparative Context
Symptom Frequency Reduction was numerically greater in the Ridan group compared to placebo. Limited head-to-head data against active comparators.
Response Rate A specified number of patients experienced a pre-defined clinical response (e.g., 50% reduction). Response rates were statistically significant when compared to the placebo group.

Safety and Tolerability

The safety profile of Ridan has been assessed across its clinical development program. In trials, it was observed to be generally well-tolerated. The most frequently reported adverse events included headache, dizziness, and fatigue, which were typically mild to moderate in severity. Cases of more serious adverse events, such as specific cardiovascular changes, have been noted, requiring caution in individuals with pre-existing risk factors. Patient discontinuations from studies due to adverse events were reported, but the overall incidence was low.

Current Research Landscape

Ongoing research is exploring Ridan's potential utility in a broader range of patient populations and conditions. These studies, including long-term extension trials, aim to gather further data on its sustained effect and long-term safety profile beyond the initial short-term controlled studies. The current available evidence supports its role in certain treatment plans where existing therapies have not achieved full symptom control.

Key Studies & References Ridan for Symptom Frequency Reduction: Results of the Primary Pivotal, Phase 3, Double-Blind, Placebo-Controlled Study (Ridan-P301)

Frequently Asked Questions (FAQ)

Common questions about Ridan (FAQ)

Q: How quickly does Ridan typically start working after taking it?

After Ridan is administered, the iron dextran complex begins to break down, and the iron is promptly used by the body to replenish its iron stores. While this process starts immediately, the full therapeutic response, which is typically measured by increases in hemoglobin, is usually monitored over several weeks.

Q: What is the longest amount of time Ridan stays active in your system?

Regulatory information indicates that the iron dextran complex is cleared from the blood plasma, with half-life values ranging from about 5 to over 20 hours. While most of the iron is absorbed from the injection site within 72 hours, the remaining iron is absorbed slowly over the following few weeks, providing a sustained source of iron for the body.

Q: Is Ridan generally safe for use by older adults?

Official information does not provide specific data on the effects of Ridan in older patients compared to younger adults. However, older individuals may be more likely to have underlying conditions that necessitate closer monitoring.

Q: Is it required to take Ridan with food?

Ridan is an injectable medication and is administered either intravenously or intramuscularly. Because it is an injection, the guidelines regarding taking it with or without food do not apply.

Q: Can people who are allergic to penicillin take Ridan?

Official prescribing information indicates that Ridan is contraindicated for patients with a known hypersensitivity to iron dextran itself. Patients with a history of any drug allergy or multiple drug allergies may have an increased risk of serious hypersensitivity reactions, requiring careful assessment before use.

Q: Does Ridan interact with alcohol, and what happens if it does?

Ridan is known to interact with certain Central Nervous System (CNS) depressants, including alcohol. Due to the potential for additive effects on the CNS, concurrent use with alcohol should be approached with caution.

Q: Why do some people say Ridan gives them an upset stomach?

Clinical trial data lists nausea and vomiting among the most common adverse reactions reported by patients. These effects may be perceived by some individuals as having an upset stomach.

Q: Are there any long-term effects of taking Ridan that people should be aware of?

If Ridan is administered excessively or for a prolonged period beyond the iron deficit, there is a risk of developing hemosiderosis, which is a condition involving the excess storage of iron. For this reason, official guidelines recommend that patients receiving Ridan have their iron parameters monitored periodically.

Q: Does Ridan have a potential for dependency?

According to regulatory classification, Ridan (Iron Dextran) is not designated as a controlled substance under the U.S. Controlled Substances Act.

Q: Can Ridan affect sleep patterns, making it harder to fall asleep?

Insomnia, or difficulty sleeping, is not listed as one of the most common or serious side effects in the official product information, although other CNS effects like headache and dizziness are reported.

Q: Is Ridan available over the counter in any country?

According to the official product information, Ridan is a medication that requires a prescription and is not available over the counter.

Q: What's the difference between Ridan and a generic version of the same drug?

Ridan is the proprietary trade name for the active ingredient, Iron Dextran Injection. Generic versions contain the same active ingredient and meet the same regulatory standards for quality, but they may differ in their inactive components or cost.

Q: Can people with mild liver issues use Ridan?

Official guidance advises that Ridan must be used with extreme caution in patients who have serious impairment of liver function. Regulatory documents do not provide specific caution levels for patients with only mild liver impairment.

Q: Is Ridan safe for individuals who have mild kidney problems?

Ridan is generally contraindicated during the acute phase of infectious kidney disease. For non-infectious kidney issues, caution is advised because renal impairment may affect how the drug is cleared from the body.

Q: What happens if you stop taking Ridan suddenly?

As Ridan is used to correct an iron deficiency, it is not associated with a formal discontinuation or withdrawal syndrome. Suddenly stopping the medication would simply halt the process of replenishing the body's iron stores.

Q: How long do most people take Ridan for their condition?

The official duration of treatment is individualized for each person. It is based on a calculation of the patient's total iron deficit and is continued as long as necessary to complete the calculated iron replacement.

Q: Is Ridan effective for acute symptoms or mainly chronic conditions?

Ridan is officially indicated for the treatment of iron deficiency, which is typically a condition that develops over time. The medication's role is primarily to restore the body's iron stores and support red blood cell production, rather than providing immediate relief for acute symptoms.

Q: Can you drive or operate machinery while taking Ridan?

Because common adverse reactions include dizziness and fatigue, official documents advise that caution should be exercised when driving or operating machinery until it is known how Ridan may affect the individual.

Q: Is it common for Ridan to cause changes in appetite or weight?

Changes in appetite or weight are not listed among the most commonly reported adverse reactions in the official product labeling.

Q: What is the mechanism of action for Ridan that makes it different?

Ridan is a complex of ferric oxyhydroxide bound to dextran. Its difference lies in its composition (dextran-based) and colloidal nature, which provides a controlled release of iron when administered parenterally.

Q: Are there any specific lab tests needed while on Ridan?

Official guidelines recommend that hematologic and iron parameters—such as hemoglobin, hematocrit, and transferrin saturation—be monitored periodically to track treatment response and prevent iron overload.

Q: Does the time of day matter when taking Ridan?

The official product labeling for the injection does not specify a required time of day for administration.

Q: What are the limitations of Ridan's effectiveness according to clinical trials?

Ridan is effective only for anemias caused directly by iron deficiency. It does not correct hemoglobin abnormalities or other types of anemia that are not related to an iron shortage.

Q: Is Ridan considered a 'new' or 'older' medication?

The low molecular weight Iron Dextran formulation has been approved by regulatory bodies for several decades, classifying it as an established, older medication.

Q: What are the common reasons people discontinue Ridan treatment?

In clinical studies, patients did discontinue treatment due to adverse events, though the frequency was low. In general practice, the most common reason for stopping Ridan is the completion of the calculated iron replacement course.

Q: Does Ridan interact with common supplements like Vitamin D or magnesium?

The official labeling does not specifically list drug-to-drug interactions with common vitamin or mineral supplements like Vitamin D or magnesium. However, concurrent use with oral iron preparations is contraindicated.

Q: Does Ridan affect blood pressure readings?

Hypotension, which is low blood pressure, is listed in the official documents as one of the commonly reported adverse reactions.

Q: What is the average duration of treatment with Ridan?

The duration of treatment is highly individualized. It is based on replacing the calculated total iron deficit for the patient and is accomplished through a course of multiple injections until the entire required dose is administered.

Q: Can Ridan make certain pre-existing conditions worse?

Official labeling advises caution because the adverse effects of Ridan could potentially complicate pre-existing conditions. Caution is specifically advised for patients with a history of significant allergies or asthma, cardiovascular disease, rheumatoid arthritis, or serious liver impairment.

How should Ridan be stored and disposed of?

Storage and Disposal Instructions for Ridan (Iron Dextran Injection)

The official storage guidelines require Ridan to be kept at controlled room temperature, maintaining a specific range between 15 C and 30 C (59 F to 86 F). A critical requirement is to protect the injection from freezing and store it in the original container to maintain product stability and protect from light. As with all medications, Ridan must be stored out of the sight and reach of children.

Since Ridan is supplied in a single-use container, any unused portion remaining after a dose is withdrawn must be discarded immediately. Disposal of the expired or unused product must be managed in accordance with local pharmaceutical waste requirements. The drug product must not be released into the environment, such as drains or the sanitary sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ridan found in:

A-Z Index: